Frank Borriello, MD, PhD, on Next Steps for SUPLEXA-101 for Solid Tumors
The scientific cofounder and chief executive officer of Alloplex Biotherapeutics discussed progress of the phase 1 trial and possible future evaluations of the therapy.
“The progress of our trial has been going very well, it’s been limited not in how quickly we can enroll patients, it’s how fast we can make the drug... We have almost completely enrolled the trial, in fact the last patient in will be sometime next month. Then we will monitor the patients over time to see how well they are doing and take blood samples to see how long this pharmacodynamic signature persists. I'm glad to say that we answered all the questions we set out to answer in this trial.”
Alloplex Biotherapeutics’ peripheral blood mononuclear cell (PBMC)-derived activated white blood cell therapy SUPLEXA-101 has demonstrated an excellent safety profile and promising clinical activity across solid and liquid tumor types. The therapy iscomprisedpredominantly of natural killer (NK) cells, natural killer T (NKT) cells, γδ T cells, and cytotoxic CD8-positive and CD4-positive T lymphocytes αβ T cells.
Data from the phase 1 trial (NCT05237206) evaluating SUPLEXA-101 were presented by Frank Borriello, MD, PhD, scientific cofounder and chief executive officer, Alloplex Biotherapeutics, at the World Oncology Cell Therapy Congress (WOCTC) held April 25-26 in Boston, Massachusetts. CGTLive spoke with Borriello to learn more about the trial evaluating SUPLEXA-101.
Borriello discussed the progress of the trial as well as some challenges it faces, including manufacturing limitations. He shared his thoughts on next steps for the therapy and other evaluations he would like to do with SUPLEXA-101, including assessing it in combination with other modes of treatment, including checkpoint inhibitors, which Borriello theorized could work well with SUPLEXA-101 due to its mechanism of action and some of its effects.
